A carregar...
A Phase II trial of Bevacizumab and High Dose Interferon Alpha-2B in Metastatic Melanoma
Bevacizumab is a humanized recombinant monoclonal antibody that neutralizes vascular endothelial growth factor, an agent with pro-angiogenic effects in melanoma. Interferon-alpha (IFN-α) has anti-angiogenic properties via its ability to down-regulate basic-fibroblast growth factor levels. We hypothe...
Na minha lista:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3116950/ https://ncbi.nlm.nih.gov/pubmed/21654521 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CJI.0b013e31821dcefd |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|